• AstraZeneca and Amgen’s Tezspire met the Phase III CROSSING trial’s main goals in eosinophilic esophagitis, improving swallowing symptoms and tissue inflammation versus placebo.
• Benefits persisted through one year; treatment also cleared visible signs of disease in some patients.
• Results were presented at United European Gastroenterology Week 2026 in Barcelona, Spain.
• The safety profile was consistent with existing indications.
• AstraZeneca plans to share the findings with regulators to pursue Tezspire’s use in eosinophilic esophagitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610200900BIZWIRE_USPR_____20261020_BW103666) on October 20, 2026, and is solely responsible for the information contained therein.